Thu, 04 Oct 2018 14:35:18 GMT
J&J ties up with Arrowhead over gene-silencing drug
Johnson & Johnson has partnered with Arrowhead Pharmaceuticals to develop and sell the gene-silencing Hepatitis B drug, planning to acquire a minority stake in a possible deal that could be valued at $3.7B.